First name,Last name,Preferred title,Overview,Position,Department,Individual
James,Womack,Distinguished Professor,"Comparative mammalian genomics with emphasis on bovids and laboratory animals. Study of evolution of gene families and genomic variation underlying disease resistance. Investigation of genetic mechanisms in innate immunity with focus on livestock, select agents, and agricultural biosecurity.",Distinguished Professor,Veterinary Pathobiology,https://scholars.library.tamu.edu/vivo/display/n0e1a49e2
Tadhg,Begley,Distinguished Professor,"The Begley Group is interested in the mechanistic chemistry and enzymology of complex organic transformations, particularly those found on the vitamin biosynthetic pathways. We are currently working on the biosynthesis of thiamin, molybdopterin, pyridoxal phosphate and menaquinone. Our research involves a combination of molecular biology, protein biochemistry, organic synthesis and structural studies and provides a strong training for students interested in understanding the organic chemistry of living systems and in pursuing careers in biotechnology, drug design or academia.
Thiamin pyrophosphate plays a key role in the stabilization of the acyl carbanion synthon in carbohydrate and amino acid metabolism. The biosyntheses of the thiamin pyrimidine and thiazole are complex and are different from any of the characterized chemical or biochemical routes to these heterocycles. We are particularly interested in cellular physiology and the mechanistic enzymology of thiamin biosynthesis. As an example of one of the complex transformations on this pathway, the figure below shows the structure of the pyrimidine synthase catalyzing the complex rearrangement of aminoimidazole ribotide (left) to the thiamin pyrimidine (right).",Distinguished Professor,Chemistry,https://scholars.library.tamu.edu/vivo/display/n498aa35b
Roderick,Dashwood,University Distinguished Professor,"Research integrates multiomic, genetic, epigenetic and immune approaches for precision oncology. Epigenetic readers, writers and erasers that reversibly regulate immune players in the antigen presentation pathway are of current mechanistic interest. Molecular and cell-based assays are combined with preclinical models coupled to polypectomy. Clinical specimens and organoids from patients undergoing colectomy provide for human translation. Supported by the NCI, NINDS/NIA, and the John S. Dunn Foundation.",John S. Dunn Chair in Disease Prevention||Distinguished Professor||Director,Institute of Biosciences and Technology||Center for Epigenetics and Disease Prevention||School of Medicine,https://scholars.library.tamu.edu/vivo/display/n7a63dbe7
Fuller,Bazer,Distinguished Professor,"Dr. Bazer's research in reproductive biology focuses on uterine biology and pregnancy, particularly pregnancy recognition signaling from the conceptus to the maternal uterus by interferon tau and estrogen from ruminant and pig conceptuses, respectively. The roles of uterine secretions as transport proteins, regulatory molecules, growth factors and enzymes and endocrine regulation of their secretion is another major research interest. The endocrinology of pregnancy, especially the roles of lactogenic and growth hormones in fetal-placental development and uterine functions are being studied. The mechanism(s) of action and potential therapeutic value of conceptus interferons and uterine-derived hematopoietic growth factors are areas of research with both pigs and sheep as models for human disease.",Distinguished Professor,Animal Science,https://scholars.library.tamu.edu/vivo/display/n7ad91d50
Stephen,Safe,Distinguished Professor,The aryl hydrocarbon receptor (AhR) is a nuclear helix-loop-helix transcription factor which forms a ligand-induced nuclear heterodimer with the AhR nuclear translocator (Arnt) protein. Research in this laboratory is focused on the molecular mechanism of crosstalk between the AhR and estrogen receptor (ER) signaling pathways in which the AhR inhibits estrogen-induced gene expression. The antiestrogenic activities of some AhR agonists are also being developed as drugs for clinical treatment of breast and endometrial cancers in women. Research on estrogen-dependent gene expression in various cancer cell lines is focused on analysis of several gene promoters to determine the mechanisms of ERa and ERb action. This includes several genes that are activated through interactions of the ER with Sp1 protein and other DNA-bound transcription factors.,Distinguished Professor||Distinguished Professor||Syd Kyle Chair,School of Veterinary Medicine and Biomedical Sciences||Biochemistry and Biophysics||Veterinary Physiology and Pharmacology,https://scholars.library.tamu.edu/vivo/display/nb20fdbd9
Richard,Gomer,Distinguished Professor,"Our laboratory is working on three areas of biomedicine, trying to move observations from basic research into the clinic. First, we are studying how the sizes of tissues and tumors are regulated, and how this can be manipulated for therapeutic purposes. As a model system, we are using the simple eukaryote Dictyostelium discoideum, which allows us to combine techniques such as biochemistry, genetics, computer modeling, and cell biology to study tissue size regulation. We have found that a secreted protein as well as the unusual molecule polyphosphate are signals in negative feedback loops that inhibit Dictyostelium cell proliferation, and we are studying the signal transduction pathway to understand similar mechanisms in humans.
Second, we are studying how some secreted proteins can make cells move away from the source of the signal. We found such a signal (called a chemorepellent) in Dictyostelium, and then found a similar signal in humans. We are working to understand the signal transduction pathway for both. The human signal repels neutrophils, and we found that this can be used therapeutically in mouse models of neutrophil-driven diseases such as rheumatoid arthritis and acute respiratory distress syndrome.
Third, we have found that a human blood protein called Serum Amyloid P (SAP) regulates a key step in the formation of scar tissue as well as the formation of the scar-like lesions in fibrosing diseases such as congestive heart failure and pulmonary fibrosis. We are studying this mechanism, and a biotech company (Promedior, now sold to Roche) we co-founded is testing SAP as a therapy for fibrosis in patients in a Phase 3 trials.",Distinguished Professor,Biology,https://scholars.library.tamu.edu/vivo/display/nf41f3898